Cathay Biotech Hits Day High with Strong 3.5% Intraday Surge

Cathay Biotech, Inc., a prominent player in the specialty chemicals sector, has shown significant activity today, gaining 3.5% as of March 9, 2026. The stock reached an intraday high of CNY 56.30, marking a notable performance against the backdrop of a declining China Shanghai Composite, which fell by 0.67% on the same day. Despite this day's positive movement, Cathay Biotech's longer-term performance metrics reveal a mixed picture. Over the past year, the stock has generated a return of 10.93%, which is considerably lower than the China Shanghai Composite's return of 22.49%. The company's market capitalization stands at CNY 30,966 million, categorizing it as a large-cap entity. Financial indicators show that while Cathay Biotech has reported positive results for the last four consecutive quarters, its return on capital employed (ROCE) remains low at 8.99%. The company has experienced a decline in operating profit over the past five years, despite a modest annual growth in net sales. With a current dividend yield of 0.75% and a price-to-book ratio of 1.76, Cathay Biotech continues to navigate a challenging market landscape.